Total Visits

Views
Phase III Study of PSC-833 (Valspodar) in Combination with Vincristine, Doxorubicin, and Dexamethasone (Valspodar/VAD) versus VAD Alone in Patients with Recurring or Refractory Multiple Myeloma (E1A95)168

Total Visits Per Month

November 2020December 2020January 2021February 2021March 2021April 2021May 2021
Phase III Study of PSC-833 (Valspodar) in Combination with Vincristine, Doxorubicin, and Dexamethasone (Valspodar/VAD) versus VAD Alone in Patients with Recurring or Refractory Multiple Myeloma (E1A95)5132312

File Visits

Views
009155.pdf1

Top country views

Views
United States112
Germany29
United Kingdom2
Sweden2
Ukraine2
Italy1
Pakistan1
Russia1
Turkey1

Top cities views

Views
Fairfield34
Woodbridge33
Kiez22
Cambridge16
Wilmington11
Houston10
Ilmenau5
Jacksonville3
Ann Arbor2
Konya1